By Annette Ikponmwonba | August 20, 2026
KEYPOINTS
- Emzor Pharma Funding SPV Plc has raised N26.70bn through a five-year fixed-rate bond.
- The Series 1 bond carries a 19 per cent interest rate and was listed on the FMDQ Exchange.
- The issuance was completed under Emzor’s N40bn Bond Issuance Programme.
- Funds will support working capital and the expansion of Emzor Pharmaceutical Industries Limited’s manufacturing operations.
- A significant portion will finance the completion of Africa’s first full-scale antimalarial Active Pharmaceutical Ingredient (API) manufacturing plant.
- The project is expected to reduce Nigeria’s dependence on imported pharmaceutical ingredients.
- The bond was reportedly oversubscribed, signalling strong investor interest in Emzor’s expansion strategy.
MAIN STORY
Emzor Pharma Funding SPV Plc has raised N26.70bn through a five-year fixed-rate bond listed on the FMDQ Exchange, providing fresh capital to expand pharmaceutical manufacturing capacity and strengthen local drug production in Nigeria, The Series 1 bond carries a 19 per cent interest rate and was issued under Emzor’s N40bn Bond Issuance Programme. Its listing was approved by the Board Listings and Markets Committee of FMDQ Exchange.
The proceeds will be used to meet working capital requirements and finance the expansion of Emzor Pharmaceutical Industries Limited’s manufacturing operations, A significant portion of the financing will support the completion of Africa’s first full-scale antimalarial Active Pharmaceutical Ingredient (API) manufacturing plant.
APIs are the active components used in the production of medicines. Increasing domestic production of these ingredients could reduce Nigeria’s reliance on imports and strengthen the country’s pharmaceutical supply chain, Emzor Pharma Funding SPV Plc was established to raise capital for its sponsor, Emzor Pharmaceutical Industries Limited, a wholly indigenous Nigerian pharmaceutical manufacturer serving the domestic and regional markets.
Emzor Chairman, Emeka Okoli, described the bond issuance as an important milestone in the company’s strategy to expand pharmaceutical manufacturing in Nigeria, He said the N26.70bn issuance was Emzor’s second domestic bond and that strong investor demand and the oversubscription of the offering demonstrated confidence in the company’s financial position and growth prospects.
Okoli added that completing the antimalarial API facility would represent a significant development for Nigeria’s pharmaceutical industry by increasing domestic manufacturing capacity and reducing dependence on imported pharmaceutical inputs.
THE ISSUES
Nigeria’s pharmaceutical industry remains exposed to external supply chains, particularly for APIs and other raw materials required to manufacture medicines, This dependence can expose local drug manufacturers to foreign exchange volatility, international supply disruptions and rising import costs. Expanding domestic API production could therefore provide greater control over a critical part of the pharmaceutical value chain.
The Emzor project also comes at a time when local manufacturing capacity is increasingly important to Nigeria’s health-security agenda, However, pharmaceutical manufacturing is capital-intensive and requires significant investment in technology, quality control, regulatory compliance, energy and specialised expertise. The long-term success of the facility will therefore depend not only on financing but also on operational efficiency and sustained demand for locally produced pharmaceutical inputs, The 19 per cent coupon also reflects the relatively high cost of raising long-term naira capital in Nigeria’s current interest-rate environment.
WHAT’S BEING SAID
Emzor management described the successful bond issuance and investor response as evidence of confidence in its expansion strategy, Emzor Chairman Emeka Okoli said completing the antimalarial API plant would strengthen local pharmaceutical manufacturing and reduce Nigeria’s dependence on imported ingredients.
Renaissance Capital Africa CEO Samuel Sule said the transaction would support the development of the API facility while contributing to national health security by increasing domestic capacity to produce critical pharmaceutical inputs, Meanwhile, FMDQ Group Chief Operating Officer Tumi Sekoni said the transaction demonstrated the ability of Nigeria’s debt capital market to connect indigenous businesses with long-term funding.
She argued that financing pharmaceutical manufacturing through the capital market could strengthen the healthcare value chain while contributing to the development of a deeper and more resilient financial market.
WHAT’S NEXT
The immediate priority for Emzor will be completing and operationalising the antimalarial API manufacturing facility, Once operational, the plant could increase Nigeria’s domestic capacity to produce pharmaceutical inputs and potentially reduce the industry’s exposure to imported APIs.
Emzor will also deploy part of the proceeds towards working capital and broader manufacturing expansion, which could increase its production capacity and support its domestic and regional market operations, For Nigeria’s capital market, the transaction could also encourage other indigenous companies in strategic sectors to explore bond financing as an alternative to conventional bank lending.
BOTTOM LINE
Emzor’s N26.70bn bond raise provides the company with long-term capital to expand pharmaceutical manufacturing and complete a major API production facility, The bigger significance extends beyond Emzor: increasing domestic API production could help Nigeria reduce import dependence, strengthen pharmaceutical supply security and deepen local participation in the healthcare value chain.
The key measure of success will be whether the new investment translates into commercially viable domestic production, lower exposure to imported pharmaceutical inputs and greater resilience in Nigeria’s medicine supply chain.
